KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cash & Current Investments (2018 - 2025)

Historic Cash & Current Investments for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $351.8 million.

  • Aurinia Pharmaceuticals' Cash & Current Investments rose 87.77% to $351.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $351.8 million, marking a year-over-year increase of 87.77%. This contributed to the annual value of $358.5 million for FY2024, which is 227.88% up from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Cash & Current Investments stood at $351.8 million for Q3 2025, which was up 87.77% from $315.1 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Cash & Current Investments ranged from a high of $466.1 million in Q4 2021 and a low of $286.4 million during Q3 2021
  • Moreover, its 5-year median value for Cash & Current Investments was $350.5 million (2023), whereas its average is $354.4 million.
  • Per our database at Business Quant, Aurinia Pharmaceuticals' Cash & Current Investments soared by 3715.22% in 2021 and then plummeted by 1645.39% in 2022.
  • Over the past 5 years, Aurinia Pharmaceuticals' Cash & Current Investments (Quarter) stood at $466.1 million in 2021, then fell by 16.45% to $389.4 million in 2022, then fell by 9.99% to $350.5 million in 2023, then rose by 2.28% to $358.5 million in 2024, then dropped by 1.86% to $351.8 million in 2025.
  • Its Cash & Current Investments was $351.8 million in Q3 2025, compared to $315.1 million in Q2 2025 and $312.9 million in Q1 2025.